Skip to content
HowShorted

Accendra Health, Inc. short interest in 2023

In 2023, Accendra Health, Inc.'s disclosed short interest ran from 7.94% of shares outstanding on 13 Jan 2023 to 7.49% on 29 Dec 2023, a change of -0.45 percentage points. The year's high was 11.60% on 29 Sep 2023 and its low 5.55% on 15 Jun 2023, averaging 8.46% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.01 days on 31 Jul 2023. Full history: Accendra Health, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Accendra Health, Inc. in 2023

2023 in figures

Start of year
7.94% (13 Jan 2023)
End of year
7.49% (29 Dec 2023)
Change
-0.45 pp
High
11.60% (29 Sep 2023)
Low
5.55% (15 Jun 2023)
Average
8.46%
Highest days to cover
14.01 (31 Jul 2023)
SEC filings marked
8

Every report in 2023

Accendra Health, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20237.94%7.98
31 Jan 20238.40%10.13
15 Feb 20238.73%8.75
28 Feb 20239.40%6.0410-K filed, results (8-K)
15 Mar 20237.87%3.54
31 Mar 20237.16%4.87
14 Apr 20237.35%7.92
28 Apr 20237.73%9.31
15 May 20236.79%5.0110-Q filed, results (8-K)
31 May 20236.23%7.99
15 Jun 20235.55%6.31
30 Jun 20236.86%5.33
14 Jul 20237.62%12.21
31 Jul 20238.28%14.01
15 Aug 202310.08%8.7810-Q filed, results (8-K)
31 Aug 202311.38%11.29
15 Sep 202311.20%7.43
29 Sep 202311.60%12.59
13 Oct 202310.96%11.49
31 Oct 20239.75%9.30
15 Nov 20238.12%6.0410-Q filed, results (8-K)
30 Nov 20237.93%12.30
15 Dec 20238.60%6.83
29 Dec 20237.49%6.48

See also: Accendra Health, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.